Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C & D Preferred Stock (Detail Textuals)

Stockholders' Deficit and Redeemable Convertible Series B and Convertible Series C & D Preferred Stock (Detail Textuals) - USD ($)		1 Months Ended										3 Months Ended				9 Months Ended
	May 03, 2017	Mar. 31, 2017	Feb. 28, 2017	Jan. 30, 2017	Dec. 31, 2016	Dec. 29, 2016	Nov. 30, 2016	Oct. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Aug. 31, 2015	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Jan. 31, 2017	Aug. 20, 2015
Equity [Line Items]
Number of shares issued for services		605,000
Research and development expense												$ 88,550			$ 80,525	$ 241,302	$ 675,840
Par value of common stock issued (in dollars per share)		$ 0.001			$ 0.001							$ 0.001	$ 0.001	$ 0.001		$ 0.001
Preferred stock, shares authorized												20,000,000				20,000,000
Series B Preferred Stock
Equity [Line Items]
Number of preferred stock and warrants sold											5,000
Conversion price						$ 0.25		$ 0.40	$ 0.80		$ 0.25	$ 0.25				$ 0.25
Number of shares converted									8	500	13,165,500	84		461		739,625
Number of shares issued in conversion									10,000	625,000		336,000		1,152,500		2,958,500
Proceeds from issuance of preferred stock and warrants											$ 5,000,000
Preferred stock, conversion rate										1,250:1		4,000:1		2,500:1		4,000:1
Liquidation preference value											$ 3,291,000
Aggregate purchase price											$ 1,000
Percentage of conversion amount											115.00%
Value of final judgment rendered against company											$ 100,000
Shares issued, price per share (in dollars per share)																			$ 0.80
Series C preferred stock
Equity [Line Items]
Warrant exercise price (in dollars per share)								$ 0.40
Number of preferred stock and warrants sold								500
Conversion price					$ 0.40	$ 0.25		$ 0.40					$ 0.25
Number of shares converted					39	75							386
Number of shares issued in conversion					97,500	300,000							1,544,000
Proceeds from issuance of preferred stock and warrants								$ 500,000
Preferred stock, conversion rate													4,000:1
Beneficial conversion feature upon issuance								$ 325,000
Aggregate purchase price								$ 1,000
Number of common stock issued upon conversion of preferred stock								2,500
Liquidation provision common stock equivalent shares								1,250,000
Series D preferred stock
Equity [Line Items]
Warrant exercise price (in dollars per share)					$ 0.25	$ 0.25								$ 0.25
Number of preferred stock and warrants sold				1,200
Conversion price				$ 0.25								$ 0.25				$ 0.25
Number of shares converted												506				1,000
Number of shares issued in conversion												2,024,000				4,000,000
Proceeds from issuance of preferred stock and warrants				$ 1,200,000
Preferred stock, conversion rate												4,000:1				4,000:1
Beneficial conversion feature upon issuance				$ 536,000				$ 175,000
Aggregate purchase price				$ 1,000
Number of common stock issued upon conversion of preferred stock				4,000
Liquidation provision common stock equivalent shares				800,000
Liquidation provision common stock equivalent value				$ 200,000
Series E Preferred Stock \| Securities purchase agreement
Equity [Line Items]
Number of shares sold	$ 0.001
Shares issued, price per share (in dollars per share)	1,000,000
Shares issued, price per share (in dollars per share)	$ 20.00
Gross proceeds received	$ 20,000,000
Technology License Agreement
Equity [Line Items]
Number of shares issued for services								100,000
Research and development expense								$ 50,000
Warrants
Equity [Line Items]
Number of shares called by warrants			125,000				40,000				6,250,000
Warrant exercise price (in dollars per share)			$ 0.41				$ 1.15				$ 1.15
Term of warrant			10 years				10 years				5 years
Value of common stock called by warrants			$ 30,000				$ 18,400
Warrants \| Series C preferred stock
Equity [Line Items]
Number of shares called by warrants							125,000
Warrant exercise price (in dollars per share)							$ 0.40
Term of warrant							5 years
Value of common stock called by warrants							$ 37,500
Warrants \| Series D preferred stock
Equity [Line Items]
Number of shares called by warrants																		480,000
Warrant exercise price (in dollars per share)																		$ 0.25
Value of common stock called by warrants																		$ 115,200
Common Stock
Equity [Line Items]
Conversion price											$ 0.80
Number of shares converted											1,250